Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of...
Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2023. FOURTH-QUARTER FINANCIAL...
Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to ...
Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium...
Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada. ...
Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase...
Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that it has taken an important step toward concluding its financial...
Endo International plc (OTC: ENDPQ) announced today the launch of its new branded video series, PD Pool Hall, which aims to educate people about...
Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase...
Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2023. THIRD-QUARTER FINANCIAL...
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6...
Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with...
Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023. SECOND-QUARTER FINANCIAL PERFORMANCE ...
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use ...
Endo International plc (OTC: ENDPQ) and Premier, Inc. (NASDAQ: PINC) announced today that Endo's Par Sterile Products business will supply Pitocin®...
Endo International plc (OTC: ENDPQ) announced today that new data from a Phase 1 study of collagenase clostridium histolyticum (CCH) in patients with ...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the...
Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™...
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to...
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole ...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and ...
Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or ...
Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals,...
Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023. FIRST-QUARTER FINANCIAL PERFORMANCE...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.